 The FDA has signed off Sonnet BioTherapeutics Holdings Incs NASDAQ: SONN Investigational New Drug IND application for SON-1010, a proprietary version of Interleukin 12 IL-12 configured using Sonnets Fully Human Albumin Binding FHAB technology. Sonnet will. 